durvalumab,tremelimumab
astrazeneca,pfizer
['poseidon', 'durva', 'nsclc', 'sclc', 'tremelimumab']
dr. presents updated survival analysis of poseidon: a phase 3 study of durvalumab +/- tremelimumab and chemotherapy in 1l nsclc with f/u of ~4y. #esmo22 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him